Replies to post #289611 on Amarin Corp Plc (AMRN)

[Lrich]

So it appears they have been obfuscating the the truth. Not once in their PRs have they stated Early 2021 until now. In all of their plans, it has always been 2020. Late 2020, but 2020. This is not helped by every email to IR where I always stated "approval" they replied that their timeline was 2020. So it appears that IR was either mistaken or misleading me.

Under careful reading, it appears that you're reasonably accurate. One can see that they changed the phrasing from "approval recommendation" to actually "approval." So they were obfuscating the truth. They never expected approval, they only expected to pass the EMA equivalent of an adcom in 2020.

April 30:

In Europe, the marketing authorization application for VASCEPA with the European Medicines Agency, or EMA, is undergoing review with an approval recommendation anticipated by Amarin near the end of 2020

August 4th:

Continued to support review of VASCEPA by the European Medicines Agency in anticipation of expected approval of VASCEPA for commercial sale in Europe in early 2021

[eightisenough]

HDG-"not rocket science" TO APOLOGIZE, its simple to give advise, "just a basic DD / knowledge" harder to say you were "wrong" ouch...